Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Short-term Investments: 2009-2017

Historic Short-term Investments for Northwest Biotherapeutics (NWBO) over the last 4 years, with Mar 2017 value amounting to $397,000.

  • Northwest Biotherapeutics' Short-term Investments fell 46.78% to $397,000 in Q1 2017 from the same period last year, while for Mar 2017 it was $397,000, marking a year-over-year decrease of 46.78%. This contributed to the annual value of $685,000 for FY2016, which is 22.69% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Short-term Investments of $397,000 as of Q1 2017, which was down 42.04% from $685,000 recorded in Q4 2016.
  • Over the past 5 years, Northwest Biotherapeutics' Short-term Investments peaked at $1.0 million during Q2 2015, and registered a low of -$1.0 million during Q2 2013.
  • Its 3-year average for Short-term Investments is $769,889, with a median of $747,000 in 2015.
  • In the last 5 years, Northwest Biotherapeutics' Short-term Investments climbed by 2.43% in 2015 and then crashed by 46.78% in 2017.
  • Northwest Biotherapeutics' Short-term Investments (Quarterly) stood at -$1.0 million in 2013, then reached $865,000 in 2014, then climbed by 2.43% to $886,000 in 2015, then decreased by 22.69% to $685,000 in 2016, then tumbled by 46.78% to $397,000 in 2017.
  • Its Short-term Investments stands at $397,000 for Q1 2017, versus $685,000 for Q4 2016 and $685,000 for Q3 2016.